Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (DE:LIA)
:LIA
LIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€29.60 - €55.50
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€2.01B
Enterprise Value€2.65B
Total Cash (Recent Filing)€428.90M
Total Debt (Recent Filing)$676.77M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Jul 30, 2025EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding54,525,692
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.82
Price to Sales (P/S)0.00
P/FCF Ratio17.67
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda9.76
Forecast
1Y Price Target
€55.12Price Target Upside39.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
LivaNova News
Bulls Say, Bears Say
Bulls Say
Competitive DataMore competitive data on sleep apnea adds confidence in the company's potential growth in this segment.
Organic GrowthOrganic revenue growth improved to 10.4% in 1Q25 from 6.8% in 4Q24.
Product ExpansionCommitment to expand oxygenator capacity affirmed into next year which could produce 'step change' in ability to supply, adding confidence to Cardiopulmonary growth trajectory.
Bears Say
Epilepsy Business RisksThere is a key risk associated with the setup for new patients in US epilepsy, with some derisking of the outlook due to a slight downward adjustment in the 1Q guide.
Share PerformanceLIVN shares are underperforming compared to the Russell 2000, with a decline of 16%.
Valuation ConcernsA recent downgrade to Peer Perform after a multi-year stint with a positive rating indicates concerns about the stock's valuation and potential risks.
Options Prices
Currently, No data available
---
Ownership Overview
0.28% Insiders
29.69%
Mutual Funds
0.23% Other Institutional Investors
50.14% Public Companies and Individual Investors
LIA FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was €29.60 and its highest was €55.50 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is €2.01B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Jul 30, 2025 which is in 67 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on May 07, 2025. The company reported €0.783 earnings per share for the quarter, beating the consensus estimate of €0.678 by €0.105.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.78.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,525,692 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of €0.783 in its last earnings report, beating expectations of €0.678. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in DE:LIA
LivaNova Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.12 (39.89% Upside)
€55.12 (39.89% Upside)
Blogger Sentiment
Bullish
DE:LIA Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $63.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.47%
12-Months-Change
Fundamentals
Return on Equity
-19.69%
Trailing 12-Months
Asset Growth
4.03%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
LIA Company Deck
LIA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful clinical trials, positioning LivaNova well for future growth. However, challenges such as the SNIA litigation liability, limited U.S. Epilepsy revenue growth, and tariff impacts were noted. Despite these challenges, the positive aspects, including revenue growth and clinical successes, outweighed the negatives.Read More>LIA Stock 12 Month Forecast
Average Price Target
€55.12
▲( 39.89% Upside)
Technical Analysis
Integra Lifesciences
―
Ufp Technologies
―
TransMedics Group
―
Cytek Biosciences
―
PROCEPT BioRobotics
―